Clostridia as live biotherapeutics: can modified Clostridium species enhance disease treatments?

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1. Day RL, Harper AJ, Woods RM, Davies OG, Heaney LM. Probiotics: current landscape and future horizons. Future Sci. OA 5(4), FSO391 (2019).
  Medline CASGoogle Scholar
• 2. Hoffman RM. Bugging tumors. Cancer Discov. 2(7), 588–590 (2012).
  Medline CASGoogle Scholar
• 3. Guo P, Zhang K, Ma X, He P. Clostridium species as probiotics: potentials and challenges. J. Anim. Sci. Biotechnol. 11, 24 (2020).
  MedlineGoogle Scholar
• 4. Theys J, Landuyt AW, Nuyts S, Van Mellaert L, Lambin P, Anne J. Clostridium as a tumor-specific delivery system of therapeutic proteins. Cancer Detect. Prev. 25(6), 548–557 (2001).
  Medline CASGoogle Scholar
• 5. Kubiak AM, Bailey TS, Dubois LJ, Theys J, Lambin P. Efficient secretion of murine IL-2 from an attenuated strain of Clostridium sporogenes, a novel delivery vehicle for cancer immunotherapy. Front. Microbiol. 12, 669488 (2021). • Describes the use of efficient gene-editing tools to attenuate and genetically engineer Clostridium.
  MedlineGoogle Scholar
• 6. Roberts NJ, Zhang L, Janku F et al. Intratumoral injection of Clostridium novyi-NT spores induces antitumor responses. Sci. Transl. Med. 6, 249ra111 (2014). • Breakthrough showing the potential of using clostridial spores as potentially effective cancer treatment, resulting in crucial findings that led to initiation of human clinical trial.
  MedlineGoogle Scholar
• 7. Theys J, Landuyt W, Nuyts S et al. Improvement of Clostridium tumour targeting vectors evaluated in rat rhabdomyosarcomas. FEMS Immunol. Med. Microbiol. 30, 37–41 (2001).
  Medline CASGoogle Scholar
• 8. ClinicalTrials.gov. Safety study of intratumoral injection of Clostridium Novyi-NT spores to treat patients with solid tumors that have not responded to standard therapies (2013) (NCT01924689). https://clinicaltrials.gov/ct2/show/NCT01924689
  Google Scholar
• 9. Janku F, Zhang HH, Pezeshki A et al. Intratumoral injection of Clostridium novyi-NT spores in patients with treatment-refractory advanced solid tumors. Clin. Cancer Res. 27(1), 96–106 (2021). •• Describes results of first-in-human clinical study to demonstrate safety of Clostridium spore injection in patients with advanced tumors.
  Medline CASGoogle Scholar
• 10. Liu SC, Minton NP, Giaccia AJ, Brown JM. Anticancer efficacy of systemically delivered anaerobic bacteria as gene therapy vectors targeting tumor hypoxia/necrosis. Gene Ther. 9(4), 291–296 (2002). • One of the first papers explicitly describing the potential of using nonpathogenic bacteria as tools for cancer treatment, paving the way for future studies.
  Medline CASGoogle Scholar
• 11. Mowday AM, Dubois LJ, Kubiak AM et al. Use of an optimised enzyme/prodrug combination for clostridia directed enzyme prodrug therapy induces a significant growth delay in necrotic tumours. Cancer Gene Ther. 29(2), 178–188 (2022).
  Medline CASGoogle Scholar
• 12. Zhang YL, Lu R, Chang ZS et al. Clostridium sporogenes delivers interleukin-12 to hypoxic tumours, producing antitumour activity without significant toxicity. Lett. Appl. Microbiol. 59(6), 580–586 (2014).
  Medline CASGoogle Scholar
• 13. Hughes J, Aston C, Kelly ML, Griffin R. Towards development of a non-toxigenic Clostridioides difficile oral spore vaccine against toxigenic C. difficile. Pharmaceutics 14(5), 1086 (2022).
  Medline CASGoogle Scholar
• 14. Kuehne SA, Minton NP. ClosTron-mediated engineering of Clostridium. Bioengineered 3(4), 247–254 (2012).
  MedlineGoogle Scholar
• 15. Woods C, Humphreys CM, Tomi-Andrino C et al. Application of transposon-insertion sequencing to determine gene essentiality in the acetogen Clostridium autoethanogenum. bioRxiv doi: 10.1101/2021.05.19.444907 (2021) (Online).
  Google Scholar
• 16. Minton NP, Ehsaan M, Humphreys CM et al. A roadmap for gene system development in Clostridium. Anaerobe doi: 10.1016/j.anaerobe.2016.05.011 (2016) (Online).
  Google Scholar
• 17. Canadas IC, Groothuis D, Zygouropoulou M, Rodrigues R, Minton NP. RiboCas: a universal CRISPR-based editing tool for Clostridium. ACS Synth. Biol. 8(6), 1379–1390 (2019). •• Describes tools that allow efficient and reliable gene editing possibilities in Clostridium, allowing fast and accurate construction of recombinant strains for various applications.
  Medline CASGoogle Scholar
• 18. Harimoto T, Danino T. Engineering bacteria for cancer therapy. Emerg. Top. Life Sci. 3(5), 623–629 (2019).
  MedlineGoogle Scholar
• 19. Rausch M, Blanc L, De Souza Silva O, Dormond O, Griffioen AW, Nowak-Sliwinska P. Characterization of renal cell carcinoma heterotypic 3D co-cultures with immune cell subsets. Cancers (Basel) 13(11), 2551 (2021).
  Medline CASGoogle Scholar
• 20. Gengenbacher N, Singhal M, Augustin HG. Preclinical mouse solid tumour models: status quo, challenges and perspectives. Nat. Rev. Cancer 17(12), 751–765 (2017).
  Medline CASGoogle Scholar